Product development teams across industries face a common manufacturing challenge: how to produce injection-molded plastic parts in quantities that are too large for 3D printing or CNC machining but too small to justify the investment in full hardened steel production tooling. The challenge is compounded by the fact that functional validation and regulatory compliance for many applications demand that prototype and development parts be produced from production-intent materials using production processes — not proxies like 3D-printed or machined alternatives that compromise material properties or geometric precision.
Low volume injection molding product development strategy addresses this challenge directly. It represents a collection of tooling and process approaches that balance the competing needs for production-quality parts, reasonable tooling cost, and reasonable timeline. For engineers managing product development, the strategies available today have expanded dramatically from what was possible even a decade ago. Tooling materials have improved, machining technologies have advanced, and supplier capabilities have grown. Programs now start faster, cost less, and deliver better part quality than they did historically. Understanding the options available in low volume injection molding product development strategy — and the tradeoffs each involves — helps engineering and procurement teams make informed decisions about which approach is right for their specific situation. Explore Hi-Rel’s comprehensive low-volume capabilities to see how strategy translates into practice.
The term “low volume” covers a wide range of annual production quantities, and the definition varies by industry context. In consumer goods manufacturing, 10,000 annual units might qualify as low volume. In medical devices or aerospace, the same quantity would be considered moderate volume. For the purposes of tooling strategy and supplier selection, a more useful definition is simply: production quantities that are too small to justify the investment in a fully hardened multi-cavity production mold, and programs that may still be in design-change phases where expensive production tooling would be premature.
The economics of tooling amortization are central to understanding why these distinctions matter. A production injection mold costing $50,000 represents $1 per part at a 50,000-unit volume, but $50 per part at a 1,000-unit volume. For programs where the total production quantity falls into the hundreds or low thousands, this per-part tooling cost dominates the total part cost. Low volume injection molding product development strategy reduces upfront tooling investment, accepting modest reductions in tool life and modest trade-offs in production efficiency or surface capability in exchange for much lower upfront cost. For limited production quantities, these tradeoffs prove economically rational.
The central decision in planning a low volume injection molding product development strategy is selecting the appropriate tooling approach. Aluminum tooling is the most widely adopted strategy. Machining costs for aluminum molds run forty to seventy percent lower than equivalent hardened steel production molds, and lead times shorten correspondingly. Modern aerospace-grade aluminum alloys such as 7075-T6 and QC-10 provide hardness and wear resistance that far exceed older aluminum grades. Tool life commonly reaches ten thousand to fifty thousand cycles depending on the application — a range that covers many low-volume injection molding programs effectively, particularly those using non-abrasive resins.
Soft steel tooling offers a middle ground between aluminum and full hardened steel. Pre-hardened P20 tool steel provides better wear resistance than aluminum and can accommodate abrasive glass-filled resins that would accelerate aluminum wear beyond acceptable limits. Aluminum tooling remains more cost-effective and faster to machine, but soft steel provides a practical option for programs with higher volume expectations or more demanding material requirements. Full hardened steel — using materials like H13 or S7 — is reserved for high-volume programs where the investment is justified by extended tool life and production throughput. Single-cavity configurations are standard in low volume injection molding, keeping tooling cost as low as possible. Multi-cavity expansion is typically reserved for programs where commercial viability has been demonstrated.
Low volume injection molding product development strategy supports the critical applications that drive many programs: product design validation, clinical trial manufacturing, and regulatory submissions. Design verification demands that functional parts be produced from production-intent materials using production processes. Engineering validation testing performed on 3D-printed or CNC-machined parts produces results that may not translate to injection-molded parts because of fundamental differences in material properties and microstructure. Material anisotropy, surface characteristics, and aging behavior all differ between additive manufacturing, machining, and injection molding.
For medical device clinical trials, regulatory expectations are particularly clear. The FDA and ISO 13485 quality management systems that govern medical device manufacturing apply equally to clinical trial production and full commercial production. Clinical trial components must be produced using approved materials, validated processes, and documented quality systems that will be used in commercial production. Suppliers without regulatory experience frequently disappoint in this context. Identifying an appropriate manufacturing partner for early clinical trial stages — rather than attempting to transition later from informal development work to regulated production — prevents costly surprises in regulatory submissions and schedule delays.
Bridge tooling addresses a specific timing challenge that frequently arises in product development. Production launch timing — when the market is ready — often differs from the completion date of full production tooling. In some cases, market readiness happens first and complete production tooling is still weeks away. In other cases, initial sales forecasts may not justify the investment in multi-cavity hardened steel production molds, but some initial production quantity is needed to establish commercial viability.
Bridge tooling uses aluminum or simple multi-cavity configurations to serve initial production quantities, typically ranging from several thousand to twenty thousand parts. Bridge molds are built with appropriate robustness to justify the tooling investment — they are not throwaway tools — but their economics depend on whether sales volumes ramp quickly enough to justify transition to full production tooling. If commercial demand grows quickly, bridge tooling retirement happens relatively soon and the incremental cost of the bridge tool is modest relative to the value of earlier market entry. If demand grows slowly or plateaus at moderate volumes, the bridge tool may serve the entire production lifecycle. Planning for this possibility — building bridge tools with appropriate durability and maintainability — ensures value is extracted regardless of the volume trajectory that actually unfolds.
An important and sometimes problematic assumption holds that lower production volumes justify less rigorous quality management. This assumption is incorrect. FDA regulations, ISO 13485 quality management standards, and IATF 16949 automotive standards do not scale with production volume. Quality requirements stem from the nature of the product and its intended use, not from how many units are produced. A two-hundred-unit medical device clinical trial run must meet the same quality standards as a one-hundred-thousand-unit commercial production run.
In non-regulated applications, the logic of quality management remains compelling even without regulatory mandates. Small production quantities mean limited margin for defects. For example, a five-percent defect rate in a five-hundred-piece run yields four hundred seventy-five acceptable parts. As a result, additional defects require unplanned production runs that disrupt customer deliveries and increase costs. Therefore, suppliers that apply production discipline to low-volume programs deliver more reliable results. In addition, first-article inspection, documented process parameters, defined non-conformance handling, and proactive quality communication help distinguish reliable suppliers from those that treat small runs as lower-priority work.
A major advantage of low volume injection molding product development strategy is access to a wide range of engineering thermoplastic resins. Medical-grade formulations, aerospace-grade materials, and specialty compounds are all available. This material flexibility creates an advantage over alternatives like 3D printing or CNC machining. Those methods often require compromises in material selection. Low-volume injection molding uses the same materials planned for production. Testing and validation on low-volume injection-molded parts directly support commercial production. Teams can confirm performance during development without uncertainty about production results.
For programs serving regulated industries, material certification and traceability become mandatory even at low volumes. Medical device programs require material certifications, resin lot documentation, and biocompatibility verification. These requirements do not scale with production quantity — they are the same for two hundred parts as for two hundred thousand. Suppliers managing regulatory documentation routinely handle this infrastructure; it does not become an exceptional burden. Non-regulated programs also benefit from this level of discipline. For example, material certifications and lot traceability confirm material properties. They also support root cause investigations if unexpected part behavior occurs.
Lead time frequently dominates program constraints in low volume injection molding product development strategy contexts. Product development timelines typically run tight, design iterations continue throughout early production, and schedule pressure intensifies. Total program lead time breaks into two phases: tooling lead time (from design completion to first samples) and production lead time (from tool completion through delivery of required quantities).
Aluminum tooling lead times vary depending on complexity. Simple to moderate complexity parts typically require two to five weeks; tighter tolerances or complex geometries may extend this to six or eight weeks. Production lead time depends on scheduling, part complexity, cycle time, and whether secondary operations are required. Proactive communication about status and risks matters most during tooling phases.
Teams should identify engineering changes during sampling as early as possible. These changes may include dimensional adjustments, gate location updates, or ejection improvements. Early action prevents issues after tooling is committed. Reliable suppliers communicate clearly and present solutions instead of only highlighting problems. They also maintain program visibility, which helps build strong relationships and supports efficient development programs.
Hi-Rel Plastics & Molding supports programs across different production scales. Low volume injection molding product development strategy programs receive the same technical and operational support as larger projects. Development builds, clinical trial supplies, bridge production, and niche commercial programs benefit from Hi-Rel’s tooling expertise, material knowledge, and quality systems. The company applies the same technical standards to every program, regardless of volume. Hi-Rel maintains strong communication, detailed quality documentation, and proactive problem-solving throughout the process.
Hi-Rel combines tooling design, material expertise, and production capabilities to support early program involvement. The team provides valuable input before committing to tooling costs. Hi-Rel understands the strict quality and documentation requirements of regulated industries, especially medical devices and aerospace. The company builds these expectations into the process from the beginning. Customers can use the same supplier for bridge production and future scaling, avoiding disruptions and re-qualification with a new manufacturing partner.
Developing a low volume injection molding product development strategy requires answers to key questions. First, determine which tooling approach fits your expected volume and timeline. What quality and documentation requirements does your end market impose? How should the program roadmap from development through potential commercial scaling? Program-specific guidance from experienced manufacturers beats generic answers. The right supplier understands not just how to make parts, but how to manage the specific constraints and tradeoffs that characterize development programs.
Hi-Rel Plastics & Molding invites inquiries from engineers and procurement professionals at any development stage. Visit hirelplastics.com to submit a project inquiry or quote request, or contact the Hi-Rel team directly to discuss your tooling strategy, material requirements, and timeline needs.
